Stock Analysis·← Pickers

ALZN

Alzamend Neuro Inc

Alzamend Neuro Inc (ALZN) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 55.0, with 1/3 trend checks passing.

Price
$1.23
2026-07-16
Trend score
1/3
Range / Mixed
RSI (14)
55.0
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

ALZN with MA50 and MA200

3.222.632.041.450.8607/3110/2401/2204/1707/15
ALZN2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$1.15+6.51% vs price
MA200
$1.77-30.62% vs price
RSI (14)
55.0Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for ALZN

Alzamend Neuro Inc (ALZN) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $1.23, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 6.5% and below the 200-day moving average by 30.6%.

Momentum and stretch context

ALZN currently has an RSI reading of 55.0, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the ALZN chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Alzamend Neuro Inc

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Sector
Healthcare
Industry
Biotechnology
CEO
Stephan Jackman
Employees
7
Market cap
$3.9M
Beta
0.14
52-week range
$0.84 – $3.60
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
15 Jun 2021
ISIN
US02262M6057
CUSIP
02262M605
Company profile data from Financial Modeling Prep. ALZN listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about ALZN

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.